Rivaroxaban Compared With Standard Anticoagulants f Venous Thromboembolism in Children: A Randomised,

Lancet Haematology,the

7, e18-e27

DOI: 10.1016/s2352-3026(19)30219-4

Citation Report

#	Article	IF	Citations
1	Safety and Efficacy of Anticoagulant Therapy in Pediatric Catheter-Related Venous Thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances, 2020, 4, 4632-4639.	6.3	51
2	Venous Thromboembolism in Children: From Diagnosis to Management. International Journal of Environmental Research and Public Health, 2020, 17, 4993.	4.2	49
3	Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 680-713.	3.3	3
4	Evidence-Based Minireview: Abnormal Uterine Bleeding in Users of Rivaroxaban and Apixaban. Hematology, 2020, 2020, 538-541.	2.5	28
5	Cancer-Associated Thrombosis in Pediatric Patients. Thrombosis Research, 2020, 191, S22-S25.	2.9	19
6	Bleeding Risk Associated With Combination Thromboprophylaxis Therapy Is Low for Patients With Coronary Artery Aneurysms After Kawasaki Disease. International Journal of Cardiology, 2020, 321, 6-11.	3.2	10
7	Rivaroxaban for the Treatment of Venous Thromboembolism in Pediatric Patients. Expert Review of Cardiovascular Therapy, 2020, 18, 733-741.	2.7	17
8	The Edoxaban Hokusai VTE PEDIATRICS Study: An Open-Label, Multicenter, Randomized Study of Edoxaban for Pediatric Venous Thromboembolic Disease. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 886-892.	3.3	32
9	Are Apixaban and Rivaroxaban Distributed Into Human Breast Milk to Clinically Relevant Concentrations?. Blood, 2020, 136, 1783-1785.	10.6	29
10	Challenges and Opportunities in the Pharmacological Treatment of Acute Venous Thromboembolism in Children. Paediatric Drugs, 2020, 22, 385-397.	4.6	9
11	Post-PE Impairment: Living With Uncertainty Following Pediatric Pulmonary Embolism. Progress in Pediatric Cardiology, 2020, 56, 101195.	0.4	0
12	Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. An Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation. Journal of Thrombosis and Haemostasis, 2020, 18, 1672-1685.	5.0	87
13	Current Approaches in the Treatment of Catheter-Related Deep Venous Thrombosis in Children. Expert Review of Hematology, 2020, 13, 607-617.	2.7	9
14	Introduction to a Review Series on Treatment of Venous Thrombotic Disorders. Blood, 2020, 135, 299-300.	10.6	4
15	The Phase 3 Pediatric Anticoagulant Era. Blood, 2020, 135, 459-460.	10.6	4
16	Diagnosis and Management of Cerebral Venous Sinus Thrombosis in Children: A Single-Center Retrospective Analysis. Child's Nervous System, 2021, 37, 153-160.	1.5	10
17	Characterizing the Use of Anticoagulants in Children Using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset). Thrombosis Research, 2021, 197, 84-87.	2.9	13
18	Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery, 2021, 61, 9-82.	3.2	720

#	Article	IF	Citations
19	Optimizing Pharmacologic Thromboprophylaxis Use in Pediatric Orthopedic Surgical Patients Through Implementation of a Perioperative Venous Thromboembolism Risk Screening Tool. Pediatric Blood and Cancer, 2021, 68, e28803.	1.7	9
20	Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug-Drug Interaction Potential. Journal of Clinical Pharmacology, 2021, 61, 656-665.	2.4	33
21	Dabigatran Etexilate and Treatment of Acute Venous Thromboembolism in Children. Lancet Haematology,the, 2021, 8, e2-e3.	14.9	1
22	Risk Assessment and Outcome of Venous Thromboembolism in Pediatric Population in an Academic Care Center of a Low-Middle Income Country. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 1076029621995895.	2.2	9
23	Thrombotic Disorders in Children. , 2021, .		2
24	Clinical Progress Note: Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Children. Journal of Hospital Medicine, 2021, 16, 168-170.	1.7	2
25	Direct Oral Anticoagulants in Treatment of Cerebral Venous Thrombosis: A Systematic Review. BMJ Open, 2021, 11, e040212.	2.7	45
26	Risk of Intracranial Hemorrhage With Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Neurology, 2022, 269, 664-675.	5.4	39
27	International Pediatric Thrombosis Network to Advance Pediatric Thrombosis Research: Communication From the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2021, 19, 1123-1129.	5.0	36
28	Pharmacokinetic Modeling and Simulation Support for Age- and Weight-Adjusted Dosing of Dabigatran Etexilate in Children With Venous Thromboembolism. Journal of Thrombosis and Haemostasis, 2021, 19, 1259-1270.	5.0	17
29	Transition of Care for Pediatric and Adult Patients With Venous Thromboembolism: A National Quality Improvement Project From the American Thrombosis and Hemostasis Network (ATHN). Thrombosis Research, 2021, 200, 23-29.	2.9	4
30	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	8.4	1,074
31	Diagnosis and Management of Pediatric Venous Thromboembolism: New Therapies on the Horizon. Pediatric Emergency Care, 2021, 37, 273.	1.1	0
32	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Thromboprophylaxis: A Systematic Review of the Literature. Seminars in Thrombosis and Hemostasis, 2021, 47, 643-653.	4.1	22
33	Venous Thromboembolism Among Noncritically Ill Hospitalized Children: Key Considerations for the Pediatric Hospital Medicine Specialist. Seminars in Thrombosis and Hemostasis, 2022, 48, 434-445.	4.1	4
34	How We Approach Thrombosis Risk in Children With COVID-19 Infection and MIS-C. Pediatric Blood and Cancer, 2021, 68, e29049.	1.7	32
35	Rivaroxaban v léčbě a prevenci recidivy žilního tromboembolismu u dětí. Vnitrni Lekarstvi, 2021, 67, 165-168.	0.2	1
36	Direct Oral Anticoagulant Safety During Breastfeeding: A Narrative Review. European Journal of Clinical Pharmacology, 2021, 77, 1465-1471.	3.8	27

#	Article	IF	Citations
37	Community-Onset Venous Thromboembolism in Children: Pediatric Emergency Medicine Perspectives. Seminars in Thrombosis and Hemostasis, 2021, 47, 623-630.	4.1	2
38	Management of Anticoagulation Associated Reproductive Tract Bleeding in Adolescent and Young Adult Females - Results of a Multinational Survey. Thrombosis Research, 2021, 203, 61-68.	2.9	3
39	Clinical Impact of Heritable Thrombophilia on Neonatal-Onset Thromboembolism: A Nationwide Study in Japan. Journal of Pediatrics, 2021, 238, 259-267.e2.	3.2	10
40	ENNOBLE-ATE Trial: An Open-Label, Randomised, Multi-Centre, Observational Study of Edoxaban for Children With Cardiac Diseases at Risk of Thromboembolism. Cardiology in the Young, 2021, 31, 1213-1219.	0.9	15
41	Treatment of Catheter-Related Arterial Thrombosis in Children: A 15-Year Single- Center Experience. Journal of Pediatrics, 2021, 239, 182-186.	3.2	11
42	Population Pharmacokinetic Analysis of Rivaroxaban in Children and Comparison to Prospective Physiologically-Based Pharmacokinetic Predictions. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1195-1207.	3.0	18
43	Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children: A Review. Chest, 2022, 161, 791-802.	5.9	61
44	Management of Submassive Bilateral Pulmonary Embolism in an Adolescent Female. Case Reports in Pulmonology, 2021, 2021, 1678528.	0.4	0
45	Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. Journal of the American Heart Association, 2021, 10, e021765.	5.8	101
46	Bleeding Issues in Women Prescribed Anticoagulation. Thrombosis Update, 2021, 5, 100068.	1.6	2
47	Dabigatran Etexilate for the Treatment of Acute Venous Thromboembolism in Children (DIVERSITY): A Randomised, Controlled, Open-Label, Phase 2b/3, Non-Inferiority Trial. Lancet Haematology,the, 2021, 8, e22-e33.	14.9	171
48	Heavy Menstrual Bleeding on Direct Factor Xa Inhibitors: Rationale and Design of the MEDEA Study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 223-230.	3.3	16
49	Safety and Efficacy of Rivaroxaban in Pediatric Cerebral Venous Thrombosis (EINSTEIN-Jr CVT). Blood Advances, 2020, 4, 6250-6258.	6.3	116
50	Optimal Dosing of Bemiparin for Deep Vein Thrombosis Treatment in Children: A Retrospective Study. Blood Coagulation and Fibrinolysis, 2021, 32, 526.	1.0	2
51	Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children. Journal of Pediatrics, 2022, 240, 14-23.	3.2	6
52	Update on Laboratory Testing and Hemostasis Assessment in Patients Receiving Direct Oral Anticoagulants (DOACs). Thrombosis Update, 2021, 5, 100084.	1.6	7
53	Treatment for Pulmonary Embolism: Anticoagulation Selection and Duration. Respiratory Medicine, 2020, .	0.0	0
54	Venous Thoracic Outlet Syndrome and Paget-Schroetter Syndrome. Seminars in Pediatric Surgery, 2021, 30, 151125.	2.6	16

#	Article	IF	Citations
55	Hemostatic and Thrombotic Disorders in the Pediatric Patient. Blood, 2022, 140, 533-541.	10.6	10
56	Andexanet Alfa for Reversal of Rivaroxaban in a Child With Intracranial Hemorrhage. Pediatric Blood and Cancer, 2022, 69, e29484.	1.7	7
57	Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children. Clinical Therapeutics, 2021, 43, 2074-2087.	3.4	14
58	A Systematic Review of the Evidence Supporting Post-Operative Antithrombotic Use Following Cardiopulmonary Bypass in Children With CHD. Cardiology in the Young, 2022, 32, 10-20.	0.9	3
59	Direct Oral Anticoagulants for Use in Paediatrics. The Lancet Child and Adolescent Health, 2022, 6, 207-214.	8.0	26
60	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 2022, 327, 129-137.	37.0	102
61	Anticoagulation in Pediatric Patients. Hamostaseologie, 2022, 42, 046-053.	1.5	22
62	Extrapolation as a Default Strategy in Pediatric Drug Development. Therapeutic Innovation and Regulatory Science, 2022, 56, 883-894.	2.9	23
63	Management Practices for Asparaginase-Associated Coagulopathy: A Survey of Pediatric Oncologists. Journal of Pediatric Hematology/Oncology, 2022, 44, e1023.	0.9	3
64	Clinical Research–When It Matters. Injury, 2023, 54, S35-S38.	2.7	1
65	Anticoagulant Treatment for Pediatric Infection-Related Cerebral Venous Thrombosis. Pediatric Neurology, 2022, 128, 20-24.	2.3	17
66	Off-Label Use of Cardiovascular Drugs in the Home Therapy of Children With Congenital or Acquired Heart Disease. American Journal of Cardiology, 2022, 166, 131-137.	2.4	11
67	Venous Thromboembolism in Pediatric Patients With Sickle Cell Disease: A North American Survey on Experience and Management Approaches of Pediatric Hematologists. Thrombosis Research, 2022, 211, 133-139.	2.9	6
68	Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 10760296221078842.	2.2	9
69	Affirming Hormone Treatment for a Transgender Adolescent After a Venous Thromboembolic Event. Journal of Pediatric Hematology/Oncology, 2022, 44, e892.	0.9	8
70	Thrombosis Complications in Pediatric Acute Lymphoblastic Leukemia: Risk Factors, Management, and Prevention: Is There Any Role for Pharmacologic Prophylaxis?. Frontiers in Pediatrics, 2022, 10, 828702.	2.4	22
71	Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options. Frontiers in Pediatrics, 2022, 10, 855162.	2.4	20
72	Practical Considerations for Use of Direct Oral Anticoagulants in Children. Frontiers in Pediatrics, 2022, 10, 860369.	2.4	28

#	Article	IF	Citations
73	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatric Drugs, 2022, 24, 13-27.	4.6	21
74	Возможности антикоагулянтной терапии у наиболее уязвимых групп пациентов. Russian Journal of Cardiology, 2022, 26, 4786.	1.9	2
75	A Systematic Review of Adherence to Anticoagulation Regimens in Pediatric Patients. Pediatric Blood and Cancer, 2022, 69, e29698.	1.7	5
76	Impact of COVID-19 Disease on Clinical Research in Pediatric and Congenital Cardiology. Archives De Pediatrie, 2022, 29, 347-353.	1.5	4
77	Hemostaseology in Pediatrics. Hamostaseologie, 2022, 42, 101-102.	1.5	0
78	Anticoagulant Therapy for 6 Weeks vs 3 Months and Recurrence and Bleeding in Patients Younger Than 21 Years With Provoked Venous Thromboembolism—Reply. JAMA - Journal of the American Medical Association, 2022, 327, 1709-1710.	37.0	8
79	Model-Informed Bridging of Rivaroxaban Doses for Thromboprophylaxis in Pediatric Patients Aged 9 Years and Older With Congenital Heart Disease. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1111-1121.	3.0	8
80	Treatment and Prevention of Venous Thromboembolism in Children: Current State and Future Directions. The Hematologist, 2022, .	0.2	1
81	A Narrative Review of Postoperative Anticoagulation Therapy for Congenital Cardiac Disease. Frontiers in Surgery, 2022, 9, 907782.	2.2	14
82	A Phase 2 Pharmacodynamic Dose-Finding, Safety, and Efficacy Study of Dalteparin for Pediatric Venous Thromboembolism Treatment in Children With and Without Cancer. Pediatric Blood and Cancer, 2022, 69, e29764.	1.7	5
83	Cancer Associated Thrombosis in Pediatric Patients. Best Practice and Research in Clinical Haematology, 2022, 35, 101352.	3.2	14
84	Headache and Changes in Artwork as a Presentation of Central Venous Sinus Thrombosis in a Child With Acute Lymphoblastic Leukemia. American Journal of Emergency Medicine, 2022, 59, 217.e1-217.e3.	2.5	2
85	Cerebral Sinovenous Thrombosis Associated With Head/Neck Infection in Children: Clues for Improved Management. Developmental Medicine and Child Neurology, 2023, 65, 215-222.	4.6	12
86	Prophylaxis of Venous Thromboembolism in Children: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2022, 48, 413-421.	4.1	9
87	Adverse Events of DOACs in Children. Frontiers in Pediatrics, 2022, 10, 932085.	2.4	7
88	Thrombotic Complications in Patients With Cancer: Advances in Pathogenesis, Prevention, and Treatment—A Report From ICTHIC 2021. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12744.	3.3	12
89	Case Report: Cardiac Multiple Thrombus and Pulmonary Embolism Associated With Mycoplasma Pneumonia Infection in a Child. Frontiers in Pediatrics, 2022, 10, 959218.	2.4	10
90	Appendix to the Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions: Pediatric Considerations. Journal of Vascular and Interventional Radiology, 2022, 33, 1424-1431.	2.2	6

#	Article	IF	Citations
91	Central Venous Catheter–Associated Complications in Pediatric Patients Diagnosed With Hodgkin Lymphoma: Implications for Catheter Choice. Supportive Care in Cancer, 2022, 30, 8069-8079.	3.6	22
92	Current Antithrombotic Therapy Strategies in Children With a Focus on Off-Label Direct Oral Anticoagulants—A Narrative Review. Children, 2022, 9, 1093.	3.0	6
93	Rivaroxaban Treatment Among Children With Cancer-Associated Thromboembolism: Real-World Data. Pediatric Blood and Cancer, 2022, 69, e29888.	1.7	12
94	Epidemiology and Management of Cerebral Venous Thrombosis During the COVID-19 Pandemic. Life, 2022, 12, 1105.	4.3	7
95	Pediatric Perioperative Clinical Pharmacy Practice: Clinical Considerations and Management: An Opinion of the Pediatrics and Perioperative Care Practice and Research Networks of the American College of Clinical Pharmacy. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 490-505.	1.6	7
96	Anticoagulation in Pediatric Cancer–Associated Venous Thromboembolism: A Subgroup Analysis of EINSTEIN-Jr. Blood Advances, 2022, 6, 5821-5828.	6.3	20
97	An Adolescent With Cerebral Thrombosis Successfully Treated With Rivaroxaban. Pediatric Emergency Care, 2022, 38, e1667.	1.1	2
98	Application of a Clinical Decision Rule and Laboratory Assays in Pediatrics: Adult Heparin-Induced Thrombocytopenia. Pediatric Blood and Cancer, 2022, 69, e29929.	1.7	4
99	Cerebral Sinovenous Thrombosis in Infants and Children: A Practical Approach to Management. Seminars in Pediatric Neurology, 2022, 44, 100993.	2.3	13
100	50 Years of Pediatric Hemostasis: Knowledge, Diagnosis, and Treatment. Seminars in Thrombosis and Hemostasis, 2023, 49, 217-224.	4.1	17
101	Successful Pulmonary Endarterectomy After Acute Pulmonary Embolism and Reversal of Acute Cor Pulmonale in an 11-Year-Old Boy With Nephrotic Syndrome. Children, 2022, 9, 1444.	3.0	6
102	Intentional Overdose of Rivaroxaban and Alcohol: A Case Report. Pediatric Blood and Cancer, 2023, 70, e29969.	1.7	1
103	Dabigatran in the Treatment and Secondary Prophylaxis of Venous Thromboembolism in Children With Thrombophilia. Blood Advances, 2022, 6, 5908-5923.	6.3	9
104	A Machine Learning Framework for Assessing the Risk of Venous Thromboembolism in Patients Undergoing Hip or Knee Replacement. Journal of Healthcare Informatics Research, 2022, 6, 423-441.	6.0	17
105	Bleeding Issues in Women Under Oral Anticoagulation. Hamostaseologie, 2022, 42, 337-347.	1.5	14
106	Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells, 2022, 11, 3214.	6.4	147
107	Direct Oral Anticoagulants in Pediatric Venous Thromboembolism: Review of Approved Products Rivaroxaban and Dabigatran. Frontiers in Pediatrics, 2022, 10, 1005098.	2.4	10
108	Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis. Vascular Health and Risk Management, 2022, 18, 793-807.	3.7	8

#	Article	IF	Citations
109	Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. Journal of the American College of Cardiology, 2022, 80, 2301-2310.	12.0	66
110	Successful Treatment of Splenic Vein Thrombosis Secondary to Acute Pancreatitis With Oral Anticoagulants: A Pediatric Case Series. American Journal of Case Reports, 2022, 23, e937599.	1.0	4
111	Real World Experience of Efficacy and Safety of Rivaroxaban in Paediatric Venous Thromboembolism. Thrombosis Research, 2023, 221, 92-96.	2.9	19
112	Once-Daily Compared With Twice-Daily Enoxaparin Maintenance Therapy Appears Safe and Efficacious in Pediatric Venous Thromboembolism. Journal of Pediatric Hematology/Oncology, 2023, 45, e655.	0.9	1
113	Thrombosis in Chronic Kidney Disease in Children. Diagnostics, 2022, 12, 2931.	4.9	6
114	Rivaroxaban for Management of Venous Thromboembolism in Pediatric Nephrotic Syndrome; A Case Report and Review of Literature. Pediatric Hematology and Oncology, 2023, 40, 688-695.	1.3	4
115	Advancing Anticoagulation for Children With Cardiac Disease. Journal of the American College of Cardiology, 2022, 80, 2311-2313.	12.0	4
116	The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 2023, 42, e1-e141.	6.3	654
117	Stroke Prevention With Anticoagulant in Cardiovascular Problem: Focus in Atrial Fibrillation. Advances in health sciences research, 2023, .	0.0	0
118	Just DOAC: Use of Direct-Acting Oral Anticoagulants in Pediatrics. American Journal of Health-System Pharmacy, 2023, 80, 412-422.	1.4	8
119	Direct Oral Anticoagulants in Pediatric Venous Thromboembolism: Experience in Specialized Pediatric Hemostasis Centers in the United States. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100001.	3.3	19
120	Use of Rivaroxaban in Children With Congenital Heart Disease: A Single-Center Case Series. Pediatric Cardiology, 2024, 45, 1295-1300.	1.9	9
121	Les thromboses veineuses en pédiatrie. Perfectionnement En Pédiatrie, 2023, 6, 26-39.	0.0	1
122	To Learn or Not to Learn From Real-World Experience on Direct Oral Anticoagulants in Pediatric Patients?. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100034.	3.3	0
123	How Do Anticoagulants Impact Menstrual Bleeding and Quality of Life? - The PERIOD Study. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100072.	3.3	29
124	Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors Versus Conventional Anticoagulants for the Treatment of Pulmonary Embolism. Cochrane Database of Systematic Reviews, 2023, 4, CD010957.	6.9	12
125	Role of Factor VIII, IX, and XI in Venous Thrombosis Recurrence Risk in Adults and Children: A Systematic Review. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100064.	3.3	14
126	The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation. Seminars in Thrombosis and Hemostasis, 2024, 50, 081-090.	4.1	46

#	Article	IF	Citations
127	Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban. Pharmaceutics, 2023, 15, 588.	7.5	25
128	Real-World Use of Apixaban for the Treatment and Prevention of Thrombosis in Children With Cardiac Disease. Journal of Thrombosis and Haemostasis, 2023, 21, 1601-1609.	5.0	34
129	Updated Guidance for Efficacy and Safety Outcomes for Clinical Trials in Venous Thromboembolism in Children: Communication From the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2023, 21, 1666-1673.	5.0	51
130	Concurrent Pansinusitis and Orbital Cellulitis Complicated by Extensive Head and Neck Venous Thrombosis in an Unvaccinated Adolescent Patient With COVID-19: A Case Report. Journal of Emergency Medicine, 2023, 65, e31-e35.	1.5	3
131	The Value of the Old and the New. Blood Advances, 2023, 7, 3683-3685.	6.3	2
132	Biomarkers in Pediatric Venous Thromboembolism: A Systematic Review of the Literature. Journal of Thrombosis and Haemostasis, 2023, 21, 1831-1848.	5.0	8
133	Hämostaseologie in der neonatologischen und pädiatrischen Intensivmedizin. Intensivmedizin Up2date, 2023, 19, 93-110.	0.0	0
134	What Did We Learn (and Did Not Learn) From the Pediatric Direct Oral Anticoagulant Trials, and How Might We Better Design Pediatric Anticoagulant Trials in the Future?. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100140.	3.3	12
135	Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors Versus Conventional Anticoagulants for the Treatment of Deep Vein Thrombosis. Cochrane Database of Systematic Reviews, 2023, 4, CD010956.	6.9	27
136	Traitement de la maladie veineuse thromboembolique à la phase aiguë. La Presse Médicale Formation, 2023, 4, 189-198.	0.1	0
137	Anticoagulant Treatment for Pediatric Splanchnic Vein Thrombosis: A Systematic Review and Meta-Analysis. Journal of Thrombosis and Haemostasis, 2023, 21, 2499-2508.	5.0	8
138	Management of Venous Thromboembolism in Pediatric Patients: Quality Assessment of Clinical Practice Guidelines and Variations in Recommendations. Thrombosis Research, 2023, 226, 107-116.	2.9	6
139	Pediatric Cardiology. , 2020, .		24
140	Thrombosis in the Neonatal Intensive Care Unit. NeoReviews, 2023, 24, e356-e369.	1.2	8
141	How I Treat Pediatric Venous Thromboembolism in the DOAC Era. Blood, 2024, 143, 389-403.	10.6	25
142	Venous Thromboembolism Characteristics, Treatment and Outcomes in Young Adults: Findings From the Registro Informatizado De Enfermedad TromboEmbólica Registry. Journal of Thrombosis and Haemostasis, 2023, 21, 2811-2823.	5.0	7
143	Rivaroxaban for Severe Superior Sagittal Sinus Thrombosis in a Child With ALL. International Journal of Hematology, 2023, 118, 309-310.	2.0	0
144	Venous Thromboembolism in Pediatric Inflammatory Bowel Disease: A Scoping Review. Journal of Pediatric Gastroenterology and Nutrition, 2023, 77, 491.	3.3	14

#	Article	IF	Citations
145	A Retrospective Study of the Clinical Characteristics of 9 Children With Pulmonary Embolism Associated With Mycoplasma pneumoniae Pneumonia. BMC Pediatrics, 2023, 23, 1-7.	2.6	30
146	Questions Around a Case of in Utero Thrombosis in a Premature Child, Concerning the Management of Anticoagulant Treatments. European Journal of Hospital Pharmacy, 2024, 31, 588-591.	1.6	0
147	Efficacy and Safety of Direct Oral Anticoagulants in the Pediatric Population: A Systematic Review and a Meta-Analysis. Journal of Thrombosis and Haemostasis, 2023, 21, 2784-2796.	5.0	18
148	Unresolved Issues in the Use of Direct Acting Oral Anticoagulants. Expert Review of Cardiovascular Therapy, 2023, 21, 913-921.	2.7	3
149	Acquired Disorders of Hemostasis. , 2024, .		0
150	Osteomyelitis and Thrombosis in a Newborn With Group A Streptococcus Infection. Prague Medical Report, 2023, 124, 293-300.	0.8	2
151	Venous Thromboembolism Prophylaxis Practices for Patients With Sickle Cell Disease Prior to and During the COVID-19 Pandemic. Blood Coagulation and Fibrinolysis, 2023, 34, 471.	1.0	1
152	A Prognostic Score to Identify Women at Increased Risk for Abnormal Uterine Bleeding During Anticoagulation for Venous Thromboembolism. Thrombosis Update, 2023, 13, 100148.	1.6	3
153	Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients With Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study. Advances in Therapy, 2024, 41, 1-22.	5.0	7
154	Real-World Experience With Edoxaban for Anticoagulation in Children at Risk for Coronary Artery Thrombosis. Cardiology in the Young, 2024, 34, 870-875.	0.9	9
155	New Oral Anticoagulants – What's New? A Systematic Review. European Journal of Medical and Health Research, 2023, 1, 4-11.	0.3	0
156	Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease. Journal of the American College of Cardiology, 2023, 82, 2296-2309.	12.0	58
157	Effects of Antiplatelet Therapy on Menstrual Blood Loss in Reproductive-Aged Women: A Systematic Review. Research and Practice in Thrombosis and Haemostasis, 2024, 8, 102295.	3.3	4
158	Efficacy and Safety of Direct Oral Anticoagulants in Pediatric Venous Thromboembolism: A Systematic Review and Meta-Analysis. Indian Journal of Pediatrics, 2025, 92, 1-7.	1.6	0
159	The Clinical and Genetic Landscape of Early-Onset Thrombophilia in Japan. Pediatric Blood and Cancer, 2024, 71, e30824.	1.7	6
160	Venous Thromboembolism in Children: The Rivaroxaban Experience. Seminars in Thrombosis and Hemostasis, 2024, 50, 866-872.	4.1	11
161	Neonatal Hemophagocytic Lymphohistiocytosis: A Meta-Analysis of 205 Cases. Pediatric Blood and Cancer, 2024, 71, e30894.	1.7	10
162	State of the Art in Pediatric Anesthesia: A Narrative Review About the Use of Preoperative Time. Journal of Personalized Medicine, 2024, 14, 182.	3.9	15

#	Article	IF	Citations
163	Improving Anticoagulation Care for Pediatric Oncology Patients: A Quality Improvement Initiative. Pediatric Quality & Safety, 2024, 9, e720.	1.1	1
164	Anticoagulation of Pediatric Patients With Venous Thromboembolism in 2023. Thrombosis Research, 2024, 235, 186-193.	2.9	13
165	Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease. Journal of the American Heart Association, 2024, 13, e028957.	5.8	8
166	Angeborene Gerinnungsstörungen. Neonatologie Scan, 2024, 13, 73-87.	0.0	0
167	Effect of Non-Vitamin K Oral Anticoagulants for Thrombosis Prophylaxis in Pediatric Heart Diseases. European Journal of Internal Medicine, 2024, 0, 138-140.	4.2	1
168	Incidence, Management, and Outcomes of Pulmonary Embolism at Tertiary Pediatric Hospitals in the United States. JACC: Advances, 2024, 3, 100895.	3.2	13
169	Cerebral Sinus Venous Thrombosis in a Teenage Girl With Heterozygeous Protein C Deficiency – Experience With Rivaroxaban for Secondary Thromboprophylaxis. Hamostaseologie, 2024, 44, T-09-07.	1.5	0
170	Managing Venous Thrombosis in a Pediatric Patient With Short Bowel and Congenital Nephrotic Syndromes: A Case Report Emphasizing Rivaroxaban Level Monitoring. Frontiers in Pediatrics, 2024, 12, 1385065.	2.4	4
171	Potential Treatment Option of Rivaroxaban for Breastfeeding Women: A Case Series. Thrombosis Research, 2024, 237, 141-144.	2.9	9
172	A Systematic Review and Meta-Analysis of the Effectiveness of Primary Thromboprophylaxis in Acute Lymphoblastic Leukemia During Early-Phase Therapy Including Asparaginase or Its Prolonged Form. Critical Reviews in Oncology/Hematology, 2024, 197, 104347.	6.9	6
173	Evaluation, Analysis, and Reporting of Medication Adherence for Clinical Trials of Anticoagulants in Children: Guidance From the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2024, 22, 2081-2092.	5.0	1
174	Efficacy and Safety of Direct Oral Anticoagulants in Cerebral Venous Thrombosis: Meta-Analysis of Randomized Clinical Trials. Clinical and Applied Thrombosis/Hemostasis, 2024, 30, 10760296241256360.	2.2	8
175	Septic Femoral and Caval Thrombophlebitis Secondary to Acute Appendicitis: A Case Report. Journal of Pediatric Surgery Case Reports, 2024, 105, 102822.	0.3	0
176	Efficacy and Safety of Antithrombotic Therapy for Preventing and Treating Pediatric Thromboembolic Disease: A Systematic Review. Scientific Reports, 2024, 14, 1-11.	5.2	2
177	Direct Oral Anticoagulant Therapy in Adolescent Venous Thromboembolism: A Systematic Review. Pediatric Blood and Cancer, 2024, 71, e31131.	1.7	3
178	Incidence of Acute Deep Vein Thrombosis in Pediatric and Adolescent Orthopedic Trauma Hospitalized Patients and Effect of Rivaroxaban Treatment. Injury, 2024, 55, 111710.	2.7	6
179	A Randomized, Controlled Trial of Continuous Heparin Infusion to Prevent Asymptomatic Catheter-Related Thrombosis at Discharge in Infants After Cardiac Surgery: The CHIP-CRT Trial. Journal of Pediatric Hematology/Oncology, 2024, 46, e406.	0.9	1
180	Selective Iliofemoral Stent Placement for Complex Pediatric Cases: A Decade of Institutional Experience. Pediatric Radiology, 2024, 54, 1540-1548.	2.8	3

#	Article	IF	Citations
181	Antithrombotic Therapy in Kawasaki Disease. Kawasaki Disease, 2023, .	1.2	3
182	Pediatric Cardiology. , 2024, .		14
183	Systematic Review of Randomized Clinical Trials on Direct Oral Anticoagulants in Pediatric Heart Diseases. Clinical and Applied Thrombosis/Hemostasis, 2024, 30, 10760296241271974.	2.2	8
184	Direct Oral Anticoagulants for Treating Acute Venous Thromboembolism in Children: Meta-Analysis of Randomized Controlled Trials. Clinical and Applied Thrombosis/Hemostasis, 2024, 30, 10760296241271386.	2.2	3
185	Factors Associated With Hospital Length of Stay Among VTE Cases: Insights From the i-RegVed Registry. Journal of Primary Care and Community Health, 2024, 15, 21501319241266815.	2.9	4
186	Exposure Matching-Based Pediatric Dose Selection for Drugs With Renal Excretion – Lessons Learned From Pediatric Development of Direct Oral Anticoagulants. Clinical Pharmacology and Therapeutics, 2024, 116, 1174-1187.	5.3	2
187	Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment. Biomedicines, 2024, 12, 1936.	4.9	30
188	Thrombotic Complications in Pediatric Cancer. Children, 2024, 11, 1096.	3.0	6
189	A Review of the Perioperative Management of Direct Oral Anticoagulants for Pediatric Anesthesiologists. Paediatric Anaesthesia, 2024, 34, 1200-1212.	1.9	4
190	A 10-Year Cross-Sectional Study Showed That Anti-Coagulation Therapy Was Not Always of Value When Treating Paediatric Cases With Septic Cerebral Venous Thrombosis. Acta Paediatrica, International Journal of Paediatrics, 2025, 114, 378-387.	2.2	1
191	A Case of Convexity Non-Aneurysmal Subarachnoid Hemorrhage Caused by Cerebral Sinus Thrombosis. International Journal of Emergency Medicine, 2024, 17, 1-6.	2.4	1
192	Clinical Characteristics, Treatment, and Outcomes of Provoked Acute Cerebral Sinovenous Thrombosis in Patients <21 Years Old: Findings From the Kids-DOTT Multinational Trial. Research and Practice in Thrombosis and Haemostasis, 2024, 8, 102605.	3.3	7
193	Advancements in Serine Protease Inhibitors: From Mechanistic Insights to Clinical Applications. Catalysts, 2024, 14, 787.	4.7	36
194	Anticoagulation With Warfarin for Paediatric Cardiac Indications: A Retrospective Study. Cardiology in the Young, 2025, 35, 407-412.	0.9	1
195	Long-Term FXa Inhibition Attenuates Thromboinflammation After Acute Myocardial Infarction and Stroke by Platelet Proteome Alteration. Journal of Thrombosis and Haemostasis, 2025, 23, 668-683.	5.0	11
196	Pulmonary Thromboembolism Due to Mycoplasma pneumoniae in Children: A Case Report and Literature Review. BMC Pediatrics, 2024, 24, 1-12.	2.6	9
197	Supportive Care During Therapy for Childhood Acute Lymphoblastic Leukemia. Pediatric Oncology, 2024, .	0.0	0
198	Systematic Analysis of the Design, Methodology, and Patient Population Characteristics of the Pediatric Direct Oral Anticoagulant Trials of Venous Thromboembolism Treatment. Journal of Thrombosis and Haemostasis, 2025, 23, 1315-1331.	5.0	5

#	Article	IF	Citations
199	Adverse Events of Factor Xa Inhibitors in Pediatric Patients: A Meta-Analysis and Pharmacovigilance Study. Paediatric Drugs, 2025, 27, 1-16.	4.6	2
200	Trombosi venosa cerebrale associata a otomastoidite con segni di ipertensione endocranica. Medico E Bambino, 2025, 44, 025-031.	0.1	0
201	The Use of DOACs in Pediatrics: Current Therapeutic and Prophylactic Indications, Cardiac Indications, and Real-World Evidence—A Review. Hamostaseologie, 2025, 45, 089-101.	1.5	13
202	Venous Thromboembolism in Children With Hodgkin Lymphoma – A Population-Based Study in Sweden, Finland, and Denmark. Thrombosis Research, 2025, 248, 109287.	2.9	4
203	Severe Chlamydia psittaci Pneumonia Complicated by Deep Vein Thrombosis: A Case Report. Frontiers in Medicine, 2025, 12, 1527556.	3.7	1
204	Higher Dose of Rivaroxaban for the Treatment of Venous Thromboembolism in a 15-Year-Old Asian Child With Antithrombin Deficiency: A Case Report and Literature Review. Medicine (United States), 2025, 104, e41629.	2.1	1
205	Acute Therapy-Related Toxicities in Pediatric Acute Lymphoblastic Leukemia. Haematologica, 2025, 110, 1923-1933.	3.9	10
206	Antiphospholipid Syndrome Presenting as Isolated Renal Vein Thrombosis: A Case Report and Review of the Literature. Journal of Medical Case Reports, 2025, 19, 123.	1.1	2
207	Anticoagulants in Children With Renal Impairment: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2025, 51, 776-787.	4.1	3
208	Recurrent Thrombosis and Major Bleeding in Children Treated for VTE. Blood Advances, 2025, 9, 3824-3831.	6.3	4
209	Prophylactic Anticoagulation in Patients With Nephrotic Syndrome in the Cure Glomerulonephropathy (CureGN) Cohort. CKJ: Clinical Kidney Journal, 2025, 18, sfaf104.	4.8	6
210	Extended-Phase Anticoagulant Treatment of Acute Venous Thromboembolism in Children: A Cohort Study From the EINSTEIN-Jr Phase 3 Trial. Lancet Haematology,the, 2025, 12, e357-e364.	14.9	9
211	Lessons From EINSTEIN-Jr and Next Steps for Extended-Phase Anticoagulation in Paediatric Venous Thromboembolism. Lancet Haematology,the, 2025, 12, e321-e323.	14.9	0
212	Safety of Direct Oral Anticoagulants in Transcatheter Pulmonary Valves: A Pediatric Institution's Experience. Pediatric Cardiology, 2026, 47, 1-6.	1.9	2
213	Rivaroxaban Treatment in Pediatric Patients With Hematologic Malignancies and Venous Thromboembolism: A Report of Four Cases. Cureus, 2025, 17, e83487.	1.3	1
214	Rivaroxaban Versus Warfarin for the Treatment of Cerebral Venous Thrombosis (RWCVT): A Randomized Controlled Trial in Resource-Limited Setting. Stroke Research and Treatment, 2025, 2025, 8893742.	2.2	4
215	Use of Direct Oral Anticoagulants in Patients With Upper Extremity Deep Vein Thrombosis: A Meta-Analysis of Efficacy and Safety. Cureus, 2025, 17, e83570.	1.3	0
216	Anticoagulant Prescribing Trends, Bleeding Events, and Reversal Agent Use in Pediatric Patients: A Retrospective, Real-World Study. PLoS ONE, 2025, 20, e0323137.	3.2	2

#	Article	IF	Citations
217	A Global Survey on Practice Changes and Barriers to the Use of Direct Oral Anticoagulants in Children. Blood Advances, 2025, 9, 3718-3727.	6.3	5
218	Low Molecular Weight Heparin Calcium Sequential Rivaroxaban for the Treatment of Cerebral Venous Sinus Thrombosis and Cortical Venous Infarction in Children With Nephrotic Syndrome: Case Report. Frontiers in Pediatrics, 2025, 13, 1566114.	2.4	0
219	American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 Updated Guidelines for Treatment of Venous Thromboembolism in Pediatric Patients. Blood Advances, 2025, 9, 2587-2636.	6.3	93
220	Swaiman's Pediatric Neurology. , 2026, .		31
221	Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism. Journal of the American Heart Association, 2025, 14, e040698.	5.8	5
222	Management of Anticoagulant Therapy in Athletes and Sportspeople: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper. Thrombosis and Haemostasis, 2025, 125, 1085-1098.	4.6	4
223	Thrombosis and Thrombophilia. , 2022, .		0
224	Case Report: Refractory Mycoplasma pneumoniae Pneumonia Complicated by Pulmonary Embolism and Infarction in a Child. Frontiers in Pediatrics, 2025, 13, 1608233.	2.4	3
225	Introduction to Venous Thromboembolism and Antithrombotic Drugs. , 2025, .		0
226	Comparison of Rivaroxaban With Warfarin for Intracardiac Thrombosis in the Pediatric Population at Different Cardiac Sites: Early Experience of Anticoagulation Approach and Treatment Outcomes. Thrombosis Research, 2025, 253, 109397.	2.9	3
227	How I Treat Pediatric Pulmonary Embolism. Blood, 2025, 146, 1643-1653.	10.6	3
228	Pediatric Venous Thromboembolism: Considerations for the Interventional Radiologist. Seminars in Interventional Radiology, 2025, 42, 289-302.	1.1	0
229	The Balancing Act After Pediatric Venous Thromboembolism. Blood Advances, 2025, 9, 3905-3906.	6.3	0
230	Updating Clinical Guidelines With Limited Evidence: Case Study of ASH/ISTH Pediatric VTE Treatment Guidelines. Blood Advances, 2025, 9, 5347-5349.	6.3	1
231	Safety of Direct Oral Anticoagulants in Surgical Bioprosthetic Heart Valves: A Paediatric Institution's Experience. Cardiology in the Young, 2025, 35, 1631-1636.	0.9	0
232	Fever in Sickle Cell Disease: Thinking Beyond Bacteremia. Pediatrics, 2025, .	5.9	1
233	Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art Review. Drug Design, Development and Therapy, 2025, 19, 7321-7331.	6.2	5
234	Reducing Anticoagulation Duration for Children After a Provoked Deep Venous Thrombosis. Journal of the American Board of Family Medicine, 2025, 38, 589-591.	1.9	2

#	Article	IF	Citations
235	Use of Anticoagulants in Children: A Cross-Sectional Study at Albert Royer Children Hospital and Cardio-Pediatric Surgery Center of Fann University Hospital in Dakar, Senegal. PAMJ Clinical Medicine, 2025, 51, 107.	0.3	1
236	Design, Synthesis, and in Vitro and in Silico Study of New Hybrid 1-(2-(4-Arylthiazol-2-Yl)Hydrazineylidene)-5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-2-Ones as Factor Xa and Factor XIa Inhibitors. Molecules, 2025, 30, 3544.	5.4	2
237	Interdisciplinary Management of Gynecologic Bleeding With Anticoagulation: A Recommended Toolkit From the Foundation for Women and Girls With Blood Disorders+ Thrombosis Subcommittee. Journal of Thrombosis and Haemostasis, 2025, 23, 3809-3817.	5.0	5
238	Case Report: Surgical Management of Giant Multiple Aneurysms After Kawasaki Disease in a Teenager. Frontiers in Pediatrics, 2025, 13, 1622729.	2.4	1
239	Treatment of a Ventricular Thrombus With Rivaroxaban in a Patient With Hypoplastic Left Heart Syndrome. Progress in Pediatric Cardiology, 2025, 79, 101875.	0.4	0
240	Cerebral Sinovenous Thrombosis in Children With Bacterial Intracranial Infections. Neurology, 2025, 105, e214278.	5.0	0
241	Cerebral Sinovenous Thrombosis in Children With Acute Bacterial Intracranial Infection. Neurology, 2025, 105, e214175.	5.0	5
242	Acute Mastoiditis–Associated Cerebral Sinus Venous Thrombosis in Children: A Retrospective Review. European Journal of Pediatrics, 2025, 184, 654.	3.4	3
243	Rivaroxaban in Chinese Children With Giant Coronary Artery Aneurysms After Kawasaki Disease. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 103211.	3.3	1
244	Considerations of Safety for Women Prescribed Apixaban or Rivaroxaban Who Breastfeed-a Physiologically Based Pharmacokinetic Analysis. Journal of Thrombosis and Haemostasis, 2026, 24, 520-529.	5.0	8
245	Frequency of, and Prognostic Factors for, Residual Thrombosis and Complete Veno-Occlusion Following Anticoagulation for Provoked Venous Thromboembolism in Patients <21 Years: Findings From the Kids-DOTT Multinational Trial. Journal of Thrombosis and Haemostasis, 2026, 24, 672-681.	5.0	0
246	Efficacy and Safety of Rivaroxaban in Neonatal Catheter-Related Thrombosis: A Single-Center Retrospective Study of 122 Cases. PeerJ, 2025, 13, e20375.	2.9	1
247	Futuros fármacos, nuevas indicaciones y vacunas COVID-19. , 2021, .		0
248	Rivaroxaban Versus Warfarin in Pediatric Intracardiac Thrombosis: A Promising Step Forward Amid Methodological Caveats. Thrombosis Research, 2026, 257, 109538.	2.9	0
249	Evaluating the Impact of an Institutional Practice Change From Warfarin to Therapeutic Rivaroxaban Post-Fontan Operation. Pediatric Cardiology, 2026, 47, 1-6.	1.9	0
250	Post-Pyloric Administration of Rivaroxaban With Therapeutic Monitoring in Pediatric Cardiac Patients: Experience in 3 Patients. Journal of Pediatric Pharmacology and Therapeutics, 2025, 30, 807-811.	1.6	0
251	Direct Oral Anticoagulant Inhibitors: Mode of Action, Clinical Aspects. Handbook of Experimental Pharmacology, 2025, 291, 1-23.	0.0	1
252	The in Vitro Anticoagulant Effect of Milvexian in Healthy Neonates and Children. Thrombosis Research, 2026, 257, 109564.	2.9	4

#	Article	IF	Citations
253	Safety and Efficacy of Anti-Coagulation for Primary and Secondary Venous Thromboembolism Prophylaxis in Hospitalized Adolescents and Young Adults With Sickle Cell Disease: An Institutional Experience. British Journal of Haematology, 2026, 208, 1380-1388.	3.2	0
254	Advances in Treatment and Prevention of Pulmonary Thromboembolism Associated With Mycoplasma pneumoniae Pneumonia in Children. Pediatric Research, 2026, 100, 1-6.	4.0	0
255	Research Priorities for Pediatric Venous Thromboembolism Prevention: Communication From the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2026, 24, 1906-1922.	5.0	4
256	Behandlung und Prävention der Venenthrombose in der Pädiatrie. Phlébologie, 2026, 55, 19-27.	0.1	0
257	Safety and Efficacy of Direct Oral Anticoagulants in Pediatric Oncology Patients: Real-World Data From Two Quaternary Care Pediatric Centers. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 103392.	3.3	0
258	Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study. Hamostaseologie, 2026, 46, T-02-02.	1.5	0
259	Clinical Guideline Highlights for the Hospitalist: Management of Pediatric Venous Thromboembolism. Journal of Hospital Medicine, 2026, 21, 531-533.	1.7	0
260	Real World Experience of Direct Oral Anticoagulant (DOAC) Use in Australian Children. Thrombosis Research, 2026, 260, 109654.	2.9	0
261	Real-World Use of Rivaroxaban for Primary Thromboprophylaxis and Cardiac Thrombosis Treatment in Congenital and Acquired Heart Disease: A Prospective Cohort Study. Scientific Reports, 2026, 16, 13923.	5.2	3
262	An International Survey on Current Practices of Management of Neonatal Catheter-Associated Venous Thromboembolism: Communication From the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2026, 24, 2661-2671.	5.0	2
263	Maladie de Kawasaki. EMC - Angéiologie, 2026, 30, 1-17.	0.0	0
264	Early Venous Thrombus Resolution in Neonates/Infants: Retrospective Review of a 20-Year Single Institution Experience. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 103455.	3.3	2
265	Efficacy and Safety of Direct Oral Anticoagulants in Pediatric Patients: A Systematic Review and Meta-Analysis. Frontiers in Public Health, 2026, 14, 1787819.	4.3	0
266	Direct Oral Anticoagulants in Children With Giant Coronary Artery Aneurysms From Kawasaki Disease: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2026, 13, 1777856.	3.2	1
267	Clinical Outcomes Following Catheter-Related Venous Thrombo-Embolism Among Children With Acute Lymphoblastic Leukemia. Thrombosis Research, 2026, 261, 109691.	2.9	0
268	Diagnóstico y tratamiento de la enfermedad tromboembólica venosa en la edad pediátrica. Recomendaciones del grupo de enfermedad tromboembólica de la Sociedad Española de Medicina Interna (SEMI), de la Sociedad Española de Trombosis y Hemostasia (SETH) y de la Sociedad Española de Hematología y Oncología Pediátricas (SEHOP). Anales De Pediatría, 2026, 105, 504238.	0.8	2
269	Emergency Reversal of Rivaroxaban With Andexanet Alfa in a Child With Hemorrhagic Brain Metastasis From Wilms Tumor. Child's Nervous System, 2026, 42, 195.	1.5	0
270	Real-World Practices in the Management of Pediatric Iliofemoral Deep Vein Thrombosis: Results of the ELITE-Kids Survey. Thrombosis Research, 2026, 262, 109696.	2.9	0

#	Article	IF	Citations
271	Enfermedad tromboembólica en pediatría: abordaje de situaciones clínicas especiales. Anales De Pediatría, 2026, 105, 504234.	0.8	1
272	Rare Pediatric Multi-System Thrombosis Post-COVID-19: A Three-Year Follow-Up Case Report and Narrative Review on Rivaroxaban for Long-Term Management. Orphanet Journal of Rare Diseases, 2026, 21, 239.	3.7	0
273	Deep Vein Thrombosis in a 14-Year-Old Boy With a Combination of May–Thurner Syndrome, Protein S Deficiency and Lupus Anticoagulant: A Case Report. Journal of Medical Case Reports, 2026, 20, 366.	1.1	0
274	The Safety of Direct Oral Anticoagulants Use During Lactation: A Systematic Review. Thrombosis Research, 2026, 262, 109708.	2.9	1
275	Spontaneous Neonatal Aortic Thrombosis Successfully Treated With Rivaroxaban. Pediatric Blood and Cancer, 2026, 73, e70403.	1.7	0
276	Rivaroxaban for Extended Anticoagulation of Pediatric Venous Thromboembolism. Translational Pediatrics, 2026, 15, 165.	1.9	0
277	Research Progress on Pediatric Mycoplasma pneumoniae Pneumonia Complicated With Pulmonary Embolism. Advances in Clinical Medicine, 2026, 16, 3436-3443.	0.1	0
278	Antiphospholipid Syndrome. , 2027, .		0
279	Rivaroxaban for Pediatric Venous Thromboembolism in Routine Clinical Practice: Effectiveness and Safety From a Real-World Cohort. Thrombosis Research, 2026, 263, 109730.	2.9	0
280	Neonatal Stroke Following Placental Abruption in a Protein C-Deficient Mother–Infant Pair. Pediatrics International, 2026, 68, e70444.	0.8	0
281	Treatment and Outcomes of Thromboembolism in Paediatric Patients With Cardiac Disease in a Cardiac ICU: A Single-Centre Retrospective Study. Cardiology in the Young, 2026, 36, 997-1003.	0.9	0
282	Venous Intervention in Children: Current Practice and Controversies. CardioVascular and Interventional Radiology, 2026, .	2.3	1
283	Клінічні випадки тромбозу глибоких вен нижніх кінцівок у дітей. Art of Medicine, 2026, .	0.2	0
284	Apixaban for Paediatric Venous Thromboembolism: Cautious Optimism. Lancet Haematology,the, 2026, 13, e428-e429.	14.9	0
285	Apixaban for the Treatment of Venous Thromboembolic Events in Paediatric Patients: An Open-Label, Multicentre, Randomised, Controlled Descriptive Trial. Lancet Haematology,the, 2026, 13, e471-e483.	14.9	1
286	Pills Over Pricks: DOAC in Pediatric Thromboses, Real World Data From an Indian Pediatric Hematology Centre, Review of Literature. Indian Journal of Hematology and Blood Transfusion, 2026, .	1.0	0
287	Venous Thromboembolism in Pediatrics: Management of Special Clinical Scenarios. Anales De Pediatría (English Edition), 2026, 105, 504234.	0.8	0
288	Can Edoxaban and Rivaroxaban Be Prescribed for Breastfeeding Mothers? The New Horizons Clinical Trial. Journal of Thrombosis and Haemostasis, 2026, .	5.0	1

#	Article	IF	Citations
289	Severe Chlamydia psittaci Pneumonia Complicated by Deep Vein Thrombosis: A Case Report and Literature Review. Frontiers in Medicine, 2026, 13, 1865706.	3.7	0
290	Relationship Between Sociodemographic Characteristics at Presentation and Outcomes of Provoked Venous Thromboembolism in United States Children: A Secondary Analysis of the Multinational Kids-Duration of Therapy for Thrombosis Trial. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 106885.	3.3	0
291	Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study. Hamostaseologie, 2026, .	1.5	0
292	Clinical Characteristics, Risk Factors, and Short-Term Outcomes of Pediatric Thrombosis in Hospitalized Non-Malignant Patients: A Single-Center Study. Journal of Health Sciences and Medicine, 2026, 9, 1045-1051.	0.4	0
293	The Use of Direct Oral Anticoagulants in Children With Congenital and Acquired Heart Disease. Frontiers in Cardiovascular Medicine, 2026, 13, 1920897.	3.2	0
294	Safety and Efficacy of Fondaparinux in Pediatric Venous Thromboembolism: A Retrospective Cohort Study. Thrombosis Research, 2026, 264, 109798.	2.9	0
295	Emergent Reversal of Intracranial Hemorrhage Using 4-Factor Prothrombin Complex Concentrate in a Pediatric Patient. Journal of Pediatric Hematology/Oncology, 2026, 48, 353-357.	0.9	0
296	Obese Adolescent With Factor V Leiden-Related Pulmonary Embolism: Case-Based Insight Into Paediatric Thrombosis Management. Diagnostics, 2026, 16, 2842.	4.9	0
297	Anticoagulation and Thrombolysis. Clinics in Chest Medicine, 2026, .	3.2	0
298	Venous Thromboembolism in Neonates, Children, and Adolescents: A Comprehensive Narrative Review of Risk Factors, Diagnosis, Treatment, and Prevention. Medicina (Lithuania), 2026, 62, 1712.	3.3	0
299	Potential Alternatives in Treatment of Kawasaki Disease to Reduce the Extremely Rare Risk of Reye Syndrome. Frontiers in Pediatrics, 2026, 14, 1856121.	2.4	0
300	Rivaroxaban. , 2026, .		0
301	Circulating Metabolites Associated With Prothrombin Time in Children With Congenital Heart Disease: An Untargeted Metabolomics Study. Metabolites, 2026, 16, 640.	4.8	0
302	Angeborene und erworbene Gerinnungsstörungen im Kindesalter. Pädiatrie Up2date, 2026, 21, 213-229.	0.1	0
303	Management of Venous Thromboembolism in Children With Acute Lymphoblastic Leukemia: Recommendations From the Harmonization Workshops of the Leukemia Committee of the French Society for Childhood Cancer (SFCE). Bulletin Du Cancer, 2026, .	0.8	0
304	Rivaroxaban as Secondary Thromboprophylaxis in Pediatric Patients With Short Bowel Syndrome. Case Reports in Hematology, 2026, 2026, 7383741.	0.8	0
305	Atrial Standstill: From Molecular Genetics to Clinical Management — A Narrative Review. Heart Rhythm, 2026, .	3.8	0
306	Antithrombotic Therapy Use in Children With Pulmonary Hypertension. Pulmonary Circulation, 2026, 16, e70418.	2.4	0

#	Article	IF	Citations
307	Apixaban for Thromboprophylaxis in Paediatric Cardiology Patients: Real-World Data From a Single Institution. Thrombosis Research, 2026, 266, 109893.	2.9	0